Innovent Biologics Showcases Research at ADA's 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 21, 2025 — Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical company focused on developing and commercializing high-quality therapies, announced its participation in the American Diabetes Association's (ADA) 85th Scientific Sessions. Innovent will showcase several groundbreaking research findings from its General Biomedicine Pipeline, including key studies on mazdutide and IBI3030, both of which target critical aspects of metabolic and cardiovascular health.

The ADA conference, a leading platform for diabetes research, will feature presentations on innovative mechanisms of action (MoA) for these compounds, further establishing their potential therapeutic impacts. Dr. Decheng Ren, an esteemed researcher at Innovent, will present a poster detailing a new anti-PCSK9 antibody-peptide conjugate, IBI3030. This compound combines unique targeting of the GLP-1 receptor (GLP-1R), glucagon receptor (GCGR), and glucose-dependent insulinotropic peptide receptor (GIPR) to enhance cardiovascular risk markers. Preliminary studies suggest that IBI3030 significantly reduces low-density lipoprotein cholesterol (LDL-c) levels while improving overall metabolic function in preclinical models (p < 0.01 vs. baseline).

"We are excited to present our findings on mazdutide and IBI3030 at such a prestigious event," stated Dr. Lei Qian, Chief Medical Officer of Innovent Biologics. "The evidence supporting mazdutide's efficacy in metabolic health continues to grow, and we believe these studies will solidify its position as a next-generation therapeutic option."

Mazdutide, a dual glucagon (GCG) and GLP-1 receptor agonist, has attracted considerable interest for its multifaceted metabolic benefits. Recent research highlights its superior efficacy in reducing liver fat and improving metabolic markers compared to conventional therapies like semaglutide. Several presentations will demonstrate mazdutide's potential in alleviating conditions such as non-alcoholic steatohepatitis (NASH) and mitigating hyperuricemia, showcasing its role in advancing diabetes treatment.

Dr. Tianpei Hong from Peking University Third Hospital will present findings indicating that mazdutide treatment significantly outperformed semaglutide in activating crucial metabolic pathways, promoting better liver health and weight management in rodent models. Additional studies will explore the compound's effects on hepatic metabolism, further elucidating its mechanism of action.

Innovent's commitment to innovation is evident as the company prepares for multiple Phase 3 trials evaluating mazdutide's efficacy in various populations, including those with obesity and type 2 diabetes. The ongoing studies aim to establish robust clinical evidence to support regulatory approvals in China.

As the global healthcare landscape evolves, Innovent Biologics remains dedicated to addressing the unmet medical needs of patients worldwide through innovative therapies. With its strong research pipeline and strategic collaborations, including a partnership with Eli Lilly, Innovent is positioned to make significant contributions to the field of metabolic disease management.

For more information about Innovent Biologics and its research initiatives, visit www.innoventbio.com or follow the company on social media platforms.